Prescription Drugs and Pharmacy News

VANCOUVER, BRITISH COLUMBIA–(Marketwire – Aug. 24, 2010) – ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCQB:APCSF) (“ALDA” or “the Company”) is monitoring reports of new “Superbugs” that are highly resistant to nearly all antibiotics, including penicillin-like antibiotics that possess broad spectrum antibacterial properties and are typically used as a last resort. The new strains of antibiotic-resistant E. coli and Klebsiella were created when genetic material that codes for an antibiotic-digesting enzyme was incorporated from other species. Such genetic “swapping” is common among bacteria and is a major cause of antibiotic resistance. Although primarily observed in Pakistan, India and the UK, similar infections have been reported in US, Canada, Australia and the Netherlands and international researchers are concerned that these new strains could become a major global health problem.

To reduce the spread of these bacteria, health authorities are recommending proper hand hygiene and disinfection procedures. Dr. Terrance Owen, President & CEO comments, “Using effective hand sanitizers and disinfectant products is an important step in keeping one’s environment safe. ALDA’s products contain 70% ethanol and benzalkonium chloride which have both proven to be very effective against E. coli and other resistant bacteria, such as MRSA. Although the threatened H1N1 pandemic did not materialize, it certainly made people aware of the need for products that can reduce the transmission of infectious diseases. The lessons learned may prove to be very useful as we face ever-increasing numbers of Superbugs.”

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T³6^® technology. The company trades on the TSX Venture Exchange under the symbol APH and on the OTCQB under the symbol APCSF. The Company was the Official Supplier to the Vancouver 2010 Olympic Winter Games and the Vancouver 2010 Paralympic Winter Games and is the Official Supplier to the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant cleaning products. The Company was also selected as one of the TSX Venture 50 companies in the Technology and Life Sciences sector for 2010.

Terrance G. Owen, Ph.D., MBA, President & CEO

ALDA Pharmaceuticals Corp.

The Units, common shares, warrants and the common shares issuable upon exercise of the warrants have not been registered under the United States Securities Act of 1933 (the “Act”) and may not be offered or sold absent registration under the Act or an applicable exemption from the registration requirements thereof. This news release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction or an exemption therefrom.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as “outlook”, “will”, “could”, “would”, “might”, “remains”, “to be”, “plans”, “believes”, “may”, “expects”, “intends”, “anticipates”, “estimate”, “future”, “plan”, “positioned”, “potential”, “project”, “remain”, “scheduled”, “set to”, “subject to”, “upcoming”, and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

HOUSTON, TX–(Marketwire – August 19, 2010) –  Nothing is worse than needing a good night’s sleep, but waking in the middle of the night with leg pain and movement. Houston Chiropractor Dr. Karen Thomason of 1960 West Chiropractic Center notes that many patients suffer from Restless leg syndrome (RLS), the irresistible urge of an individual to move their legs.

Restless leg syndrome can begin at any age, but it is more common in older patients and women, who are more likely to develop this condition than men. The symptoms include cramping, tingling, aching and a “crawling” sensation in the legs, thighs and calves. RLS affects most people at night, and lying down and trying to relax activates the symptoms. As a result, sleep is affected and exhaustion often ensues.

While many turn to prescription medications, Dr. Thomason notes that chiropractic treatment can alleviate many of the unpleasant symptoms of RLS and allow patients to have an uninterrupted night’s sleep, which is essential for good health.

“The symptoms of RLS are very uncomfortable and difficult to withstand,” said Dr. Thomason. “We have helped many patients with treatments to release the tension in the legs and calves. Chiropractic sessions have been effective in alleviating pain naturally, without the use of drugs.”

RLS affects as many as 12 million Americans and Houston chiropractic care is available through 1960 West Chiropractic to enable individuals suffering from RLS, or many other physical conditions such as back pain, neck pain, headaches, leg numbness and many more physical ailments, to heal naturally.

About 1960 West Chiropractic Center
1960 West Chiropractic Center was founded by native Houstonian, Dr. Karen S. Thomason. The practice, specializing in Chiropractic Care, has proven results in realigning or resetting the body to proper balance. Chiropractic treatment has been effective for patients in recovery from job injuries, accidents, sports injuries and chronic pain. Services include Chiropractic care, massage therapy, X-Ray Services and onsite active rehabilitation. 1960 West Chiropractic is a member of the Texas Chiropractic Association and the American Chiropractic Association.

Click here to see all recent news from this company

TEMPE, AZ–(Marketwire – August 18, 2010) –  Current figures estimate that spending on health care in the U.S. is about 16% of its GDP. In 2007, an estimated $2.26 trillion was spent on health care in the United States, or $7,439 per capita. Health care costs are rising faster than wages or inflation, and the health share of GDP is expected to continue its upward trend, reaching 19.5% of GDP by 2017.

With health care reform recently approved, the debate over costs is fierce. Some say costs will be controlled or reduced; others claim that costs will spiral out of control. Regardless, Medicare, in its present form, is not sustainable, according to the Congressional Budget Office.

On the sidelines in the debate over care and costs is a rising trend toward alternative health care, known as naturopathy. Tempe, Arizona based naturopathic physicians Danite Haller, N.D. and Eric Udell, N.D. at Arizona Homeopathic Associates are enjoying a thriving practice in spite of national economic woes. “With many people out of work and not having company health insurance, they are finding that naturopathic medicine is an effective and affordable way to go,” claims Udell.

Naturopathic medicine is based on the belief that the human body has an innate healing ability. Naturopathic doctors teach their patients to use diet, exercise, lifestyle changes and innovative natural therapies to enhance their bodies’ ability to ward off and combat disease.

Dr. Haller describes the difference between conventional medicine and naturopathy, “In naturopathy we don’t use medication to alleviate or mask symptoms. We strive to identity the causes of the symptoms and provide non-invasive treatments and no pharmaceutical medicines.” Haller and Udell have chosen one aspect of naturopathy — homeopathy. First used in 1796 by a German physician, homeopathy uses specially prepared remedies based on the law of “similar.” This means substances that cause certain symptoms can be use in extremely diluted form to encourage the body in the healing process. These remedies are all natural and have no side effects.

Homeopathic remedies are extremely cost effective, costing less than traditional medications. Naturopathic care, which requires greater doctor care and interaction than conventional medicine is less costly, too.

For more information on this alternative form of medical care, see www.azhomeopathic.com.

Click here to see all recent news from this company

ALISO VIEJO, CA–(Marketwire – August 17, 2010) –  CNS Response (OTCBB: CNSO) submitted an application to FDA for obtaining 510k clearance for its Referenced-EEG (rEEG®) service as a Class II device in April 2010. CNS Response CEO George Carpenter commented, “Based on our latest discussions with the FDA, it’s clear that 510k clearance will not occur in September, as we had originally hoped. We also thought shareholders should know that our business continues to move forward, with greater focus on pharma bioinformatics and clinical services.”

The Company has always considered rEEG to be a reference data service, not a traditional medical device under FDA regulation, since rEEG is a reference database accessed by qualified medical professionals over the web. However, in December 2009, Jeffrey Shuren, MD — now director of the Center for Devices and Radiological Health — presented a clear and reasonable route to 510k clearance, citing several packaged software products currently regulated as Class II devices, and which the FDA believed to be similar to rEEG. Based on this clear pathway and the commercial advantages of such approval, the Company filed for 510k clearance in April. In late July, however, reviewers indicated that they now believe rEEG is not substantially equivalent to those software products, but is in fact a new device with a new indication for use requiring a 510k filing with different predicate devices or application for Premarket Approval (PMA). 

Carpenter continued, “This brings us back to our original position, which was never waived. The growth of the internet and medical informatics have led to an explosion of similar services which offer physicians objective information about patient treatment options. rEEG was developed by physicians to solve a critical information gap in medicine, and it is now the largest reference database correlating electrophysiology (EEG) with standard pharmacotherapy. We will continue to grow our non-device business, and we will also continue our dialog with the FDA toward a mutual understanding of its regulatory relationship to rEEG services.”

About CNS Response
Today, most physicians are able to base treatment on objective test data, such as EKGs, MRIs, blood tests, etc. Broadly speaking, such advances have not yet come to those physicians practicing psychiatry.

Referenced-EEG was developed by physicians to provide objective, personalized, statistical data on patient neurophysiology. In clinical trials, physicians using rEEG data have consistently achieved superior clinical results compared to physicians using trial and error pharmacotherapy.

The Company announced publication last week of results from its most recent clinical trial in The Journal of Psychiatric Research, in which physicians using Referenced-EEG (rEEG^®) had success rates reaching 65 percent for patients with treatment-resistant depression.

To read more about the benefits this patented technology provides physicians, patients and insurers, please visit the CNS Response website, www.cnsresponse.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company’s filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.

NEW YORK, NY–(Marketwire – August 12, 2010) –  Vaccines continue to be the success story for pharmaceutical companies, with the world market for preventative vaccines totaling $22.1 billion in 2009, up from $19 billion in 2008, according to healthcare market research publisher Kalorama Information. Kalorama’s new report, “Vaccines 2010: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry,” notes that the worldwide vaccine market is predicted to increase at a compound annual rate of 9.7% during the next five years, as new product introductions continue and the use of current products expands further. 

“We’ve forecasted a high growth rate for vaccines over the past few years and market events have matched our predictions,” said Bruce Carlson, publisher of Kalorama Information. “The vaccine business is not without its risks, but for some companies, vaccines were the only bright spot in their portfolio in 2009. It’s not a surprise therefore that development is heavy in this sector, and that will contribute to growth over the next five years.”

Vaccines are commonly segmented into two target markets, adult and pediatric. According to Kalorama Information, the pediatric vaccine market is larger, accounting for more than half of the total market. Pediatric vaccines are also growing at a faster rate than adult vaccines and this is expected to continue over the next five years. Pneumococcal and “combination” DTaP vaccines are driving growth in the pediatric sector, while influenza and hepatitis vaccine products are driving sales in the adult segment of the market. Future growth in adult vaccines will be driven by increased acceptance and new products. 

The worldwide vaccine market is dominated by five major competitors: Merck & Co, GlaxoSmithKline, Sanofi Pasteur, Pfizer, and Novartis. These companies have made earning a greater share of the vaccine market part of their marketing and research strategies. GlaxoSmithKline is in the lead with nearly a quarter of the world market in 2009, largely due to its influenza products Fluvarix and Hiberix, according to Kalorama. 

More information is available from Kalorama Information’s report, “Vaccines 2010: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry,” including market forecasts, company profiles, and trends in the industry. The report can be found at: http://www.kaloramainformation.com/redirect.asp?progid=79452&productid=2684026.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

JOHANNESBURG, SOUTH AFRICA–(Marketwire – August 11, 2010) – Virtual Pharma Rep™ (VPR), an e-marketing firm with a patent pending, e-detailing marketing platform, today announced that it will be launching South Africa’s first e-detailing campaign, in partnership with a major South African pharmaceutical company. This is the first ever marketing project of its kind in the South African pharmaceutical industry.

Virtual Pharma Rep™ recently opened operations in South Africa, and is a pioneer in bringing a new virtual sales approach to the market that revolutionizes expensive pharmaceutical sales models, supplements existing sales forces and reduces marketing and promotional budgets significantly. Virtual Pharma Rep™ leverages technology to deliver powerful multimedia messages to doctors that educate and provide important product and service information directly from the pharmaceutical company, much like a field sales rep. This new sales approach is designed to provide consistent, controlled and fully customized messages to multiple doctors simultaneously through an online communication channel, along with various ways for doctors to communicate with companies in return. Messages can be accessed by doctors at their convenience, when their schedule allows, thereby saving precious time in their schedules.

“New marketing strategies are necessary to stay competitive in any industry, and this is especially true now within South Africa as marketing trends shift due to new technological advances,” said Jim Rediehs, CEO of Virtual Pharma Rep. “We are most excited to be launching our revolutionary marketing concept in the South African pharmaceutical market. We will demonstrate that e-detailing, in conjunction with current marketing and sales strategies, is an effective way to penetrate target audiences, even those in hard to reach white spaces. E-detailing fills in communication gaps, and therefore reaches more doctors, which ultimately provides patients with better access to the pharmaceutical products they require for a healthy life.”

For more information, visit www.virtualpharmarep.com

About Virtual Pharma Rep™

Virtual Pharma Rep is revolutionizing the pharmaceutical industry by leading the paradigm shift to virtual sales support and service models that enhance or replace existing and expensive pharmaceutical marketing strategies. Virtual Pharma Rep is led by a highly experienced team of pharmaceutical industry veterans and growth strategists. For more information visit www.virtualpharmarep.com

SOPHIA ANTIPOLIS, FRANCE–(Marketwire – August 4, 2010) – www.nicox.com

NicOx S.A. (NYSE Euronext Paris: COX) today announced the decision to close
the US headquarters of NicOx Inc. with effect from August 31, 2010. The
decision follows a review of the Group’s structure and requirements after
the US Food and Drug Administration (FDA) said it could not approve its
lead drug candidate naproxcinod, which is expected to at least
significantly delay any potential US launch.

NicOx plans to discuss possible next steps as early as possible with the
FDA and to continue to pursue the European regulatory process for
naproxcinod. NicOx will also actively seek to enter into partnerships for
naproxcinod in Europe and the rest of the world as well as for other
products in its pipeline whilst also pursuing appropriate in-licensing and
M&A opportunities.

The Company had cash and cash equivalents of ?128.4 million at June
30, 2010, and no long-term debt. It also has development partnerships on
its pipeline with Bausch + Lomb, Merck & Co. Inc and Ferrer Grupo.

Michele Garufi, Chief Executive Officer of NicOx, commented: “We very much
regret having to close our operations in the US and we are grateful for the
hard work and dedication of all our employees over the past few years. They
have played a major role in raising awareness among scientists and
clinicians of naproxcinod’s potential medical and clinical value. As we
seek to work out possible next steps for naproxcinod in the US and to
pursue the approval process in Europe, it is essential that we manage our
resources in the most effective manner.”

Risks factors which are likely to have a material effect on NicOx’s
business are presented in the 4th chapter of the ” Document de
référence, rapport financier annuel et rapport de gestion 2009 ”
filed with the French Autorité des Marchés Financiers (AMF) on
March 5, 2010 and available on NicOx’s website (www.nicox.com) and on the
AMF’s website (www.amf-france.org).

The Company notably draws the investors’ attention to the following risk
factors:

– Risques liés à la dépendance de la Société
à l’égard du naproxcinod (Risks related to the Company’s
dependence on the success of its lead product naproxcinod)

– Risques commerciaux et développements cliniques (Clinical
developments and commercial risk)

– Risques liés aux contraintes réglementaires et à la
lenteur des procédures d’approbation (Risks linked to regulatory
constraints and slow approval procedures)

– Manque de capacités dans les domaines de la vente et du marketing
(Lack of sales and marketing capabilities)

– Incertitude relative aux prix des médicaments et aux régimes de
remboursement, ainsi qu’en matière de réforme des régimes
d’assurance maladie (Uncertainty on drug pricing and reimbursement policies
and on the reforms of the health insurance systems)

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company
focused on the research, development and future commercialization of drug
candidates. NicOx is applying its proprietary nitric oxide-donating R&D
platform to develop an internal portfolio of New Molecular Entities (NME)
for the potential treatment of inflammatory, cardio-metabolic and
ophthalmological diseases.

NicOx’s lead investigational compound is naproxcinod, an NME and a first-
in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-
inflammatory drug candidate developed for the relief of the signs and
symptoms of osteoarthritis (OA). In July 2010, the U.S. Food and Drug
Administration (FDA) provided a Complete Response Letter to the New Drug
Application (NDA) for naproxcinod stating that it does not approve the
naproxcinod application. The naproxcinod Marketing Authorization
Application (MAA) submitted by NicOx in December 2009 is currently under
review by the European Medicines Agency (EMA).

In addition to naproxcinod, NicOx’s pipeline includes several nitric oxide-
donating NMEs, which are in development internally and with partners,
including Merck & Co., Inc. and Bausch + Lomb, for the treatment of
hypertension, cardiometabolic diseases, eye diseases and dermatological
diseases.

NicOx S.A. is headquartered in France and is listed on Euronext Paris
(Compartment B: Mid Caps).

This press release contains certain forward-looking statements. Although
the Company believes its expectations are based on reasonable assumptions,
these forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ materially from
those anticipated in the forward-looking statements.

For a discussion of risks and uncertainties which could cause actual
results, financial condition, performance or achievements of NicOx S.A. to
differ from those contained in the forward-looking statements, please refer
to the Risk Factors (“Facteurs de Risque”) section of the Document de
Reference filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on NicOx S.A.’s website
(http://www.nicox.com).

This information is provided by HUGIN

VANCOUVER, BRITISH COLUMBIA–(Marketwire – Aug. 3, 2010) – ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCQB:APCSF) (“ALDA” or “the Company”) announces that it is seeking an extension of the exercise period of an aggregate of 6,000,000 outstanding share purchase warrants issued as part of the non-brokered private placement of common share units which closed on September 16, 2009. Pursuant to the proposed extension, the applicable exercise period will be extended by one further year, from September 16, 2010 to September 16, 2011. The warrant exercise price of $0.40 per share will remain the same. Insiders of the Company hold 50,000 of the outstanding share purchase warrants subject to the proposed amendment.

The proposed extension is subject to the warrant holders entering into definitive amendment agreements and the acceptance of the TSX Venture Exchange. The amendment provides ALDA with an extended opportunity to receive funding for general corporate purposes from existing warrant holders.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T³6^® technology. The company trades on the TSX Venture Exchange under the symbol APH and on the OTCQB under the symbol APCSF. The Company was the Official Supplier to the Vancouver 2010 Olympic Winter Games and the Vancouver 2010 Paralympic Winter Games and is the Official Supplier to the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant cleaning products. The Company was also selected as one of the TSX Venture 50 companies in the Technology and Life Sciences sector for 2010.

Terrance G. Owen, Ph.D., MBA, President & CEO

ALDA Pharmaceuticals Corp.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as “outlook”, “will”, “could”, “would”, “might”, “remains”, “to be”, “plans”, “believes”, “may”, “expects”, “intends”, “anticipates”, “estimate”, “future”, “plan”, “positioned”, “potential”, “project”, “remain”, “scheduled”, “set to”, “subject to”, “upcoming”, and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

NEW YORK, NY–(Marketwire – August 3, 2010) –  A robust over-the-counter (OTC) drug market exists in less developed regions, where OTC is often the most practical distribution method, according to medical market research publisher Kalorama Information. According to “The Worldwide Over-the-Counter (OTC) Drug Market,” a recent Kalorama report, non-prescription pharmaceutical sales account for between 8% and 30% of total pharmaceutical markets around the globe, with higher ratios of OTC sales in developing nations. Kalorama estimates the OTC drug market in Asia-Pacific and Africa is worth $21 billion with an average growth of 4% annually.

In 2009, the OTC drug market in the developing BRIC nations (Brazil, Russia, India, and China) claimed a higher percentage of total pharmaceutical sales compared to more developed nations such as the United States, which had an OTC market share of 8%. India paced the quartet of burgeoning world powers with an OTC market share of 33%. China (23%), Russia (19%), and Brazil (17%) followed suit with double-digit OTC share claims.

Developed nations Japan and Australia are also important international players in the OTC market, though the greatest opportunities for growth and expansion remain in China, India, Singapore, Malaysia, and Indonesia, among other developing nations.

“It’s simply easier to work around regulatory and distribution issues in these countries by distributing product direct to consumers where it is medically possible,” said Melissa Elder, analyst for Kalorama Information. “It’s not a new trend, but we see sales to developing nations continuing to drive up the portion of all Pharma sales that are OTC.”

Additionally, in nations such as China the general population has an increasing ability to purchase products due to staggering increases in per capita Gross National Income between 2000 and 2005. Combined with the large population of China, there is now a more significant market opportunity for companies to sell products, especially OTC products. In comparison, the U.S. experienced a mere fraction of China’s per capita GNI growth during the same period, while Latvia was the only country with a greater GNI increase than China.

The state of the economy, lifestyles, cultures, and the condition of medical care all contribute to the percentage of people that seek to self-medicate. People are highly influenced by the cost of healthcare and will purchase OTC products in order to save money. Because a large number of consumers in India are uninsured, the majority of the population is forced to be conscious of health spending. As an example the report says that nearly 80% of India’s population actively self-medicates according to the report. In Kenya nearly 60% of the population actively self-medicates for similar reasons.

“The Worldwide Over-the-Counter (OTC) Drug Market” investigates the strategies pharmaceutical companies are using in the international OTC market. The report includes market sizes and forecasts in five general segments. For further information visit:
http://www.kaloramainformation.com/redirect.asp?progid=79415&productid=2661910.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

SAN DIEGO, CA–(Marketwire – July 29, 2010) –  Medistem Inc. (PINKSHEETS: MEDS) announced today publication of a peer reviewed paper identifying a molecule found on the company’s lead product, the universal donor Endometrial Regenerative Cell (ERC), as a key component of cellular escape from immune attack. The study, titled “Resistance of neonatal porcine Sertoli cells to human xenoantibody and complement-mediated lysis is associated with low expression of alpha-Gal and high production of clusterin and CD59,” was published in the journal Xenotransplantation as a collaboration between Medistem and the Institute of Organ Transplantation, Tongji Hospital, in Wuhan, China.

The study found that CD59, a molecule made by ERC, plays an important role in protecting cells from immune rejection when placed in contact with immune components from another species. The ERC is a mesenchymal-like stem cell that Medistem discovered in 2007 capable of generating heart, lung, brain, muscle, blood vessel, pancreas, liver, fat and bone tissue. The original description of this cell, which won the “Publication of the Year Award” may be found at http://www.translational-medicine.com/content/pdf/1479-5876-5-57.pdf.

“One of the fundamental aspects of Medistem’s lead product, the Endometrial Regenerative Cell (ERC), is its ability to function without the need for tissue matching. In other words, the ERC stem cells act as universal donors. We have previously published that human ERC are effective in treating mice having a condition that resembles critical limb ischemia (see paper http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf). We now believe that expression of the molecule CD59 on ERC may be one of the mechanisms by which these human cells can be used not only as a universal donor for humans, but also for the treatment of numerous diseases across a variety of animal species,” said Thomas Ichim, CEO of Medistem.

Medistem has filed an IND with the FDA for treatment of critical limb ischemia (severe obstruction of the arteries that leads to decreased blood flow to the extremities) with ERC. Currently the company is in the process of completing additional experiments requested by the FDA before clinical trials can commence. Through physician-initiated compassionate use mechanisms Medistem has already published on human use of ERC in treatment of heart failure, Duchenne Muscular Dystrophy, and multiple sclerosis. A recent peer-reviewed paper describing ERC in treatment of heart failure may be found at http://www.intarchmed.com/content/pdf/1755-7682-3-5.pdf.

About Medistem Inc.

Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company’s lead product, the endometrial regenerative cell (ERC), is a “universal donor” stem cell being developed for critical limb ischemia. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf. 

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

id=”nav_links”>

TUSTIN, CA–(Marketwire – July 29, 2010) –  US-based Radient Pharmaceuticals Corporation (NYSE Amex: RPC) announced today Perceptive Imagineering has launched a Spanish language website (www.perceptive-imagineering.com/onko-sure) adapted for the Latin American culture in support of the product commercialization for RPC’s proprietary, USFDA-approved Onko-Sure® in vitro diagnostic (IVD) cancer test. 

As RPC’s distribution partner for Central America, South America, Mexico and the Caribbean, Perceptive Imagineering is responsible for commercialization efforts, including product registration, marketing, sales and support for the licensing and distribution of Onko?Sure in these regions. The newly launched site is a companion to RPC’s corporate websites: Radient-Pharma.com and Onko-Sure, and delivers detailed information on Radient Pharmaceuticals, Onko-Sure and Onko-Sure product sales and distribution in Latin American and surrounding regions. This website also includes a valuable FAQ section with answers to the most commonly asked questions about Onko-Sure, scientific literature regarding the test, basic information about cancer and cancer testing in Latin America, RPC’s CLIA laboratory testing resources and general information on cancer screening, testing and treatment.

According to Douglas MacLallan, Chairman and CEO of Radient Pharmaceuticals, “The launch of this new site supports our commercialization efforts in Latin America and serves as a critical communication tool in this geographical region. The site is an invaluable resource to educate our key Latin American audiences, which include cancer patients, the medical and healthcare community at large, existing and prospective investors, partners and suppliers on the Company and Onko-Sure and Onko-Sure’s merits as a non-invasive, simple blood test for cancer screening and testing.”

Perceptive specializes in assisting US medical companies in bringing their products into Latin America. Perceptive Imagineering, LLC is led Dr. Nancy Alvarez, and, under her leadership, her company is well?suited to lead the licensing, distribution and commercialization efforts for RPC’s Onko?Sure cancer test in this market.

Onko-Sure IVD cancer test is a simple, non-invasive, patent-pending and regulatory-approved in vitro diagnostic (IVD) test used for the detection, screening, and monitoring of various types of cancer. The test enables physicians and healthcare professionals to effectively monitor and/or detect certain types of cancers by measuring the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in the blood. FDP levels rise dramatically with the progression of cancer. Onko-Sure™ is approved by the US FDA for the monitoring of colorectal cancer and by Health Canada as a lung cancer detection and monitoring test.

About Radient Pharma:
Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is a US-based pharmaceutical company specializing in the research, development and sales of In Vitro Diagnostic Cancer tests. The Company’s focus is on the discovery, development & commercialization of unique high?value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve outcomes for patients. Our Onko?Sure™ IVD cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. For additional information on RPC and its portfolio of cancer products visit the Company’s corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

VANCOUVER, BRITISH COLUMBIA–(Marketwire – July 27, 2010) – ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCQB:APCSF)(PINK SHEETS:APCSF) (the “Company”) announces that, as a result of prevailing market conditions, the private placement financing originally announced on April 15, 2010 (and subsequently revised as disclosed in the Company’s news releases of April 28^th and May 28^th), will not be proceeding on the terms disclosed. The Company is proceeding with a smaller private placement of $325,000 to be used for general corporate purposes by the sale of 3,250,000 share purchase units on a private placement basis, pursuant to registration and prospectus exemptions of applicable securities laws and is subject to acceptance by the TSX Venture Exchange, at $0.10 per unit. Each Unit consists of one common share of ALDA and one non-transferable share purchase warrant entitling the holder to acquire one additional common share of ALDA at a price of $0.20 per common share for a period of two (2) years from the date of the issuance of the purchase warrant with an accelerated exercise provision attached to each warrant commencing on the day following the expiry of any applicable hold period on the underlying Common Share, stating that if, for ten consecutive trading days, the closing price of the listed shares of the Company exceeds $0.40 then the exercise period of the warrants will be reduced to a period of 10 days following such trading days. All securities issued will be subject to a four month restricted period and will bear a restrictive legend accordingly.

Insiders of ALDA will be subscribing for 25% of the offering, constituting a related party transaction pursuant to Multilateral Instrument 61-101 and TSX Venture Exchange Policy 5.9 which is exempt from the requirement to obtain an independent valuation pursuant to Section 5.5(b) of MI 61-101 and the requirement to obtain minority shareholder approval pursuant to Section 5.7(1)(b) of MI 61-101. Their participation will be on the same terms as arm’s length investors, and such insiders’ shareholdings in the Company will increase as a result of any such participation. The revised private placement is intended to close within the next week as soon as the requisite approvals of the TSX Venture Exchange are obtained.

The Company also wishes to clarify that a report on the TSX Venture Exchange website on Tuesday, July 20, 2010 that an insider sold 108,500 shares at $0.12 was not correct. The Company has confirmed that the transaction did not involve a current insider of the Company and was incorrectly designated as such on the TSX Venture Exchange website.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T³6^® technology. The Company trades on the TSX Venture Exchange under the symbol APH and on the OTCQB under the symbol APCSF. The Company was the Official Supplier to the Vancouver 2010 Olympic Winter Games and the Vancouver 2010 Paralympic Winter Games and is the Official Supplier to the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant cleaning products. The Company was also selected as one of the TSX Venture 50 companies in the Technology and Life Sciences sector for 2010.

Terrance G. Owen, Ph.D., MBA, President & CEO, ALDA Pharmaceuticals Corp.

The Units, common shares, warrants and the common shares issuable upon exercise of the warrants have not been registered under the United States Securities Act of 1933 (the “Act”) and may not be offered or sold absent registration under the Act or an applicable exemption from the registration requirements thereof. This news release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction or an exemption therefrom.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as “outlook”, “will”, “could”, “would”, “might”, “remains”, “to be”, “plans”, “believes”, “may”, “expects”, “intends”, “anticipates”, “estimate”, “future”, “plan”, “positioned”, “potential”, “project”, “remain”, “scheduled”, “set to”, “subject to”, “upcoming”, and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

ROCKVILLE, MD–(Marketwire – July 26, 2010) –  MarketResearch.com has announced the addition of Business Insights’ new report “Drug Discovery Collaborations between Academia and the Pharmaceutical Industry: Cultural factors, intellectual property considerations, case studies, and future trends,” to their collection of Pharmaceuticals market reports. For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2738133.

The pharmaceutical and biopharmaceutical industries are engaged in a business environment which is witnessing a dramatic escalation of R&D costs, key patent expiries, and sustained high attrition rates for new molecules in development.

In response, pharmaceutical companies have recognized the need to expand the range of creative stimuli for their research processes in order to reinvigorate their drug discovery pipelines. Consequently the industry has sought to develop external collaborations not only with other companies but also more frequently with academia, to obtain access to new technologies to enhance their drug discovery capabilities and to in-license candidates for further development. Indeed, collaboration is becoming an essential component of today’s drug discovery efforts and it is commonly undertaken with multiple partners through an often iterative, continuous, and long lasting process, which adds to the complexity of efficiently managing both the collaboration itself and the data generated.

This report explores the opportunities and challenges that are presented by collaboration with university researchers as well as identifying the key inputs from both the industrial and academic partners. The different organizational cultures and structures are examined along with consideration of the goals for each institution and the issues these create. The report discusses the various types of agreement which can be used, highlights legislation of importance to the appropriate protection of intellectual property, and presents case studies of notable collaborations In addition the report offers thoughts on the future for collaborative agreements and the benefits they will bring to both parties.

Questions Answered within the report include…

• What are the key drivers influencing change to a more collaborative approach to R&D in the pharmaceutical industry?
• What are the latest developments in the collaborative approach to R&D and which models represent the best opportunities for the pharmaceutical industry?
• What are the issues and concerns over the evolving collaborative R&D paradigms?
• What are the intellectual property management issues that should be considered by each party?
• Which changes in patent legislation are of greatest relevance to the formation of collaborations in different countries?
• What are the different types of academia-industry collaborations?
• What are the pros and cons for each party in academia-industry collaborations?
• What are the critical success factors for academia-industry collaborations?
• What are the main factors to take into account when negotiating academia-industry collaborations?
• What are the cultural, change management and goal alignment challenges?
• What are the future directions for academia-industry collaborations?

For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2738133.

Click here to see all recent news from this company

SOPHIA ANTIPOLIS, FRANCE–(Marketwire – July 22, 2010) – www.nicox.com

NicOx S.A. (NYSE Euronext Paris: COX) today announced the receipt of a
Complete Response Letter from the U.S. Food and Drug Administration (FDA)
related to the New Drug Application (NDA) for naproxcinod. Naproxcinod is
being developed for the relief of the signs and symptoms of osteoarthritis.

The FDA informed NicOx that its review of the NDA is complete and that it
does not approve the naproxcinod application. The FDA has recommended
conducting one or more long-term controlled studies to assess the
cardiovascular and gastrointestinal safety of naproxcinod. Additional
studies to demonstrate a clinically meaningful therapeutic benefit
attributable to the nitric oxide donation were also recommended. No
clinical efficacy studies were requested.

NicOx plans to discuss the Complete Response Letter and potential next
steps as early as possible with the FDA.

The naproxcinod Marketing Authorization Application (MAA) submitted by
NicOx in December 2009 is currently under review by the European Medicines
Agency (EMA).

NicOx remains well funded and had cash, cash equivalents and financial
instruments of ?138.5 million at the end of March 2010. The Company
will publish its financial results for the first half of 2010 on July 30,
2010. NicOx has no long-term debt and is constantly reviewing all aspects
of its cost base to ensure careful conservation of its funds.

NicOx has a broad pipeline of nitric oxide (NO)-donating New Molecular
Entities (NMEs) targeting the therapeutic areas of inflammatory,
cardiometabolic and ophthalmological diseases. NicOx has built a network of
strong partnerships for the development of some of its promising lead
compounds, including alliances with Merck & Co., Inc., Bausch + Lomb and
Ferrer.

Risks factors which are likely to have a material effect on NicOx’s
business are presented in the 4th chapter of the ” Document de
référence, rapport financier annuel et rapport de gestion 2009 ”
filed with the French Autorité des Marchés Financiers (AMF) on
March 5, 2010 and available on NicOx’s website (www.nicox.com) and on the
AMF’s website
(www.amf-france.org).

The Company notably draws the investors’ attention to the following risk
factors:

– Risques liés à la dépendance de la Société
à l’égard du naproxcinod (Risks related to the Company’s
dependence on the success of its lead product naproxcinod)

– Risques commerciaux et développements cliniques (Clinical
developments and commercial risk)

– Risques liés aux contraintes réglementaires et à la
lenteur des procédures d’approbation (Risks linked to regulatory
constraints and slow approval procedures)

– Manque de capacités dans les domaines de la vente et du marketing
(Lack of sales and marketing capabilities)

– Incertitude relative aux prix des médicaments et aux régimes de
remboursement, ainsi qu’en matière de réforme des régimes
d’assurance maladie (Uncertainty on drug pricing and reimbursement policies
and on the reforms of the health insurance systems)

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company
focused on the research, development and future commercialization of drug
candidates. NicOx is applying its proprietary nitric oxide-donating R&D
platform to develop an internal portfolio of New Molecular Entities (NME)
for the potential treatment of inflammatory, cardio-metabolic and
ophthalmological diseases.

NicOx’s lead investigational compound is naproxcinod, an NME and a first-
in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-
inflammatory drug candidate developed for the relief of the signs and
symptoms of osteoarthritis (OA). In July 2010, the FDA provided a Complete
Response Letter to the New Drug Application (NDA) for naproxcinod stating
that it does not approve the naproxcinod application. The naproxcinod
Marketing Authorization Application (MAA) submitted by NicOx in December
2009 is currently under review by the European Medicines Agency (EMA).

In addition to naproxcinod, NicOx’s pipeline includes several nitric oxide-
donating NMEs, which are in development internally and with partners,
including Merck & Co., Inc. and Bausch + Lomb, for the treatment of
hypertension, cardiometabolic diseases, eye diseases and dermatological
diseases.

NicOx S.A. is headquartered in France and is listed on Euronext Paris
(Compartment B: Mid Caps).

This press release contains certain forward-looking statements. Although
the Company believes its expectations are based on reasonable assumptions,
these forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ materially from
those anticipated in the forward-looking statements. For a discussion of
risks and uncertainties which could cause actual results, financial
condition, performance or achievements of NicOx S.A. to differ from those
contained in the forward-looking statements, please refer to the Risk
Factors (“Facteurs de Risque”) section of the Document de Reference filed
with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on NicOx S.A.’s website
(http://www.nicox.com).

CONTACTS

www.nicox.com

NicOx

Gavin Spencer – Vice President Business Development Tel +33 (0)4 97 24 53
00 – [email protected]

Media Relations Financial Dynamics

Europe

Guillaume Granier (France) – Tel: +33 (0)1 47 03 68 10 –
[email protected]

Stéphanie Bia (France) – Tel: +33 (0)1 47 03 68 10 –
[email protected]

Jonathan Birt (UK) – Tel +44 (0)20 7269 7205 – [email protected]

United States

Robert Stanislaro – Tel +1 212 850 5657 – [email protected]

Irma Gomez-Dib – Tel +1 212 850 5761 – [email protected]

NicOx S.A.,

Les Taissounières – Bât HB4 – 1681 route des Dolines – BP313,
06906 Sophia Antipolis cedex, France. Tel. +33 (0)4 97 24 53 00 – Fax +33
(0)4 97 24 53 99

This information is provided by HUGIN

KANSAS CITY, MO–(Marketwire – July 21, 2010) –  The Translational Medicine Alliance Forum will convene October 13-14, 2010 at the Mandarin Oriental in Washington, DC. This year’s Forum will be hosted by three organizations with the common interest of accelerating translational research to the patient.

The Forum brings together leaders from academia, government agencies, and pharmaceutical, biotechnology and venture industries to work toward developing a deeper understanding of effective models to enable and accelerate the progress of translational medicine. Through focused, dynamic sessions and exclusive networking opportunities, attendees have the opportunity to learn about breakthrough approaches and progress on current best practices in translational medicine collaborations.

“Translational medicine holds some of the most promising advancements, and through this Forum, we are able to help facilitate and encourage a steady pathway to success for current and future research,” said Lesa Mitchell, vice president of Advancing Innovation, Ewing Marion Kauffman Foundation. The Kauffman Foundation helped found the Translational Medicine Alliance in 2007.

This Forum will focus on the following topics: regulatory science, lessons from the most experienced translational models, how and why rare disease and pediatric medicine are changing the landscape, transparency and access to data and reverse engineering translational science starting with the patient. 

The 2010 Forum is cosponsored by the Ewing Marion Kauffman Foundation, FasterCures and the Council for American Innovation. Registration for the Forum is now open. Early bird rates are available now through August 16, 2010, with a rate of $595 for corporate and $200 for academic and not-for-profit registrations. Space is limited. To register for the Forum, visit https://www.regonline.com/2010_translational_medicine_alliance_forum or call 866-831-3243.

Translational Medicine Alliance

The TransMed Partnership was formed in March 2007 to tap into the best ideas of thought leaders and develop an integrated strategy to support and advance the most promising technologies. The Alliance was founded by the Kauffman Foundation, Pfizer, Johnson and Johnson, Biogen Idec, FasterCures, Washington University, St. Louis (WUSTL) School of Medicine, BioVentures for Global Health, the Center for Emerging Technologies, BIOCOM, BIOTECanada, and LifeTech Innovations. For more information about the Alliance, please visit www.translationalmedicinealliance.org.

TUSTIN, CA–(Marketwire – July 21, 2010) – Radient Pharmaceuticals Corporation (NYSE Amex: RPC), a US-based pharmaceutical company specializing in the research, development and sales of In Vitro Diagnostic (IVD) cancer tests, announced today it has entered into an exclusive distribution agreement with AMDL Australia Pty Ltd. to market and commercialize RPC’s Onko-Sure™ in vitro diagnostic (IVD) cancer test in Australia and New Zealand.

Led by a strong management team of well-respected physicians and diagnostics professionals, AMDL Australia Pty Ltd. is an established, privately?owned distributor of healthcare products to laboratories, clinics, hospitals and other health care providers and research organizations throughout Australia and New Zealand. The company is the newest addition to Radient Pharmaceuticals’ portfolio of international distributors and under the terms of the agreement, will market, sell and distribute at minimum 3700 Onko?Sure IVD cancer test kits for use as a monitoring test for colorectal cancer (CRC) in Australia and New Zealand. AMDL Australia also holds responsibility for developing and executing a full-scale marketing strategy to drive product awareness and engage healthcare decision makers, thought?leaders, lab directors, physicians, patients and healthcare consumers in product purchases. Targeted distribution channels will include medical centers, hospitals, clinical laboratories, university labs.

According to Douglas MacLellan, Chairman and CEO of RPC, “We are extremely pleased to further expand the commercial availability of Onko-Sure through this partnership with AMDL Australia, a leading distributor in Australia and New Zealand. AMDL Australia has a well-established and significant sales force with a successful track record in these markets where we have not yet established a full commercial sales presence for Onko-Sure. Through this partnership, Onko-Sure will be available sooner and to more patients than otherwise possible in these selected markets.”

AMDL Australia’s Dr Chris Dirks remarked, “Epidemiological evidence estimates there are more than 13,000 new cases of CRC in Australia annually. CRC is a leading cause of cancer death in this country and through national cancer screening programs with the use of Onko-Sure we can enable health care providers with the ability to provide early detection, treatment and more vigilant monitoring, which in turn can lead to decreased mortality rates. We are pleased to be the exclusive distributor of Onko-Sure in the Australian and New Zealand markets.”

Onko?Sure is a simple, non?invasive, patent?pending and regulatory?approved in vitro diagnostic test that enables physicians and their patients to effectively monitor and/or detect certain types of cancers by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP). FDP levels rise dramatically with the progression of cancer. The test is approved for laboratory use in Australia and follows FDA clearance for the post treatment phase monitoring of patients with CRC. The test is a standard ELISA test can be requested for patients with CRC on regular pathology request forms by their physicians.

RPC Contact Information:
For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company’s corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of our Onko-Sure™ In Vitro Diagnostic cancer test. Our focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve outcomes for patients. Radient Pharmaceutical’s current Onko-Sure™ cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. To learn more about our company, people and potentially life-saving cancer test, visit www.radient-pharma.com.

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

TIBURON, CA–(Marketwire – July 19, 2010) –  NovaVision, Inc., headquartered in Boca Raton, Fla., filed for Chapter 7 Bankruptcy in the State of Florida (Case #10-21343-PGH) on April 28, 2010 after more than seven years of continuous operation. The bankruptcy trustee has engaged The Magnum Group, Inc., to solicit offers for NovaVision’s assets which include the NovaVision Visual Restoration Therapy (VRT) system, a neuroplacticity platform that has been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of stroke, traumatic brain injury, amblyopia (“lazy eye”) and optic nerve damage. 

NovaVision has received a total investment of $49,200,000 since its founding in 2003 and has generated revenues of approximately $1,000,000 each year for the past three years. The company’s non-invasive computer-based neuroplacticity products have treated more than 3,000 patients worldwide. NovaVision estimates the total market opportunity for its portfolio of products to exceed 300,000 units in U.S. optometry, ophthalmology, neurology, and primary care practices as well as rehabilitation centers. 

“NovaVision was the first company to commercialize a non-invasive, computer-based therapeutic model to help the large population of patients that have lost visual functionality and independence due to stroke or brain injury,” said Holger Weis, former Chief Financial Officer for NovaVision. “While it is extremely unfortunate that NovaVision has fallen victim to the current economic environment, there remains huge market potential to keep these treatments alive in the marketplace while continuing to commercialize the numerous patents and discoveries that NovaVision has invested nearly fifty million dollars to advance.”

NovaVision was founded in 2003 by Bernhard Sabel, PhD, who led the original research team that published a double-blind placebo controlled clinical study in Nature Medicine in 1998. This landmark study, as well as many subsequent studies, has validated VRT as a clinically proven treatment to restore lost vision resulting from stroke, traumatic brain injury, or other acquired brain injuries. In 2003, NovaVison’s Visual Restoration Therapy was granted 510(k) clearance by the U.S. FDA for the diagnosis and treatment of these conditions.

VRT treatment has been offered at leading neurological, eye and rehabilitation centers throughout the U.S. and Europe and it can be prescribed by eye doctors, neurologists or physiatrists. Data from a recent retrospective study showed that more than 70 percent of U.S. patients who underwent a six-month treatment protocol with NovaVision VRT showed significant improvement in their vision. 

“Visual field defects are common after brain insults such as stroke and traumatic brain injury and they cause significant disability,” said neurologist Jose G. Romano, MD, FAHA, Associate Professor of Clinical Neurology, Director, Cerebrovascular Division, University of Miami Miller School of Medicine. “In my experience, VRT has positively impacted the majority of patients treated with improvements in reading, mobility and avoidance of injuries. Techniques such as VRT are an important addition to the limited rehabilitation options available to these patients.”

The Company has also developed devices that aid in the diagnosis of visual field deficits, including an Inpatient Device for assessment and therapeutic use in rehabilitation centers and the Head Mounted Perimeter, a portable and ADA-compliant instrument to aid in the assessment of visual field deficits. Additional indications for VRT include age-related macular degeneration, glaucoma, diabetic retinopathy and attention deficit disorder/attention deficit hyperactivity disorder. 

“VRT is the only restorative therapy available for patients suffering from visual field loss following stroke or trauma,” said Michael Rosenberg, MD, Director of Neurology and Neuro-ophthalmology, New Jersey Neuroscience Institute at JFK Medical Center in Edison, New Jersey. “I have been providing VRT to my patients for more than five years with results similar to published research in which 70 percent of patients achieved marked improvements in visual function. It is my sincere hope that I will again be able to offer VRT as a treatment option very soon.”

NovaVision maintains a strong and broad based portfolio of patent protection on its methods and apparatus in the form of issued patents and applications, both domestically and internationally. In the U.S., the Company has a total of five issued patents and 12 pending applications. The international patent portfolio includes one issued patent and more than 30 pending applications. NovaVision’s wholly-owned European subsidiary, NovaVision AG, located in Magdeburg, Germany is also available for sale. 

To learn more about NovaVison’s assets and patents, please contact Randy McDonald, Managing Director and President of The Magnum Group, Inc. at [email protected] or (415) 435-5550.

About The Magnum Group

Founded in the San Francisco Bay Area in 1980, The Magnum Group, Inc. is the largest business development firm serving the ophthalmic (vision care) industry. Specializing in acquisition and financing agreements, strategic alliances, joint venture, licensing and distribution contracts, The Magnum Group represents both Buyers and Sellers and has managed more than $250 million in transactions since 1995. For more information, please visit http://www.themagnumgroup.com/

Click here to see all recent news from this company

ONTARIO, CA–(Marketwire – July 15, 2010) – Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products is pleased to announce they are in the process of adding an additional prescription drug to their product line. This drug known as Fortex is used for the relief of pain and inflammation of musculoskeletal conditions such as arthritis and muscle soreness.

Fortex will be prescribed by orthopedic surgeons, rheumatologists, general practitioners and pharmacists throughout Canada. Under the terms of the exclusive license agreement, Axxess Pharma will have sole rights to manufacture and market the prescription drug in Canada. The Company anticipates this prescription drug will provide a significant source of residual revenue due to the continued increase of senior citizens and overworked population.

For more information, please contact Investor Relations at (973) 351-3868.

About Axxess Pharma, Inc.:

Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.

Safe Harbor

Statements about the Company’s future expectations and all other statements in this press release other than historical facts, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.

The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words “anticipate,” “estimate,” “expect,” “intend,” “plans,” “projects,” and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.

TUSTIN, CA–(Marketwire – July 14, 2010) –  Radient Pharmaceuticals Corporation (NYSE Amex: RPC), a US-based pharmaceutical company, has announced the launch of its newly designed website located at www.radient-pharma.com and new corporate video featured on RPC’s new corporate website and recently launched Onko-Sure™ product website located at www.onkosure.com.

RPC’s new corporate website offers visitors ease of use and informative, comprehensive in-depth information on RPC’s company, management, products, and strategic plans. This site also provides a more comprehensive and informative investor relations section that will be of great interest to existing shareholders, prospective investors, the investment community in general, and the Company’s customers and strategic partners. Additionally, site visitors can now access more in-depth information on RPC’s corporate and product commercialization strategy, timeline and progress through RPC’s new corporate video which is accessible via www.radient-pharma.com and www.onkosure.com.

According to Douglas MacLellan, Chairman and CEO of Radient Pharmaceuticals, “Radient Pharmaceuticals is committed to providing and maintaining strong communication with our existing shareholders and prospective investors; the medical and healthcare community at large; and partners, suppliers, and customers. It is our expectation that with this new , informative and highly user-friendly design, RPC’s refreshed website will provide a more effective platform for the dissemination of news, updates, webcasts and pertinent shareholder and investor relations information concerning the company. As our company grows, we will continue to update our website with features and content that help our key audiences learn about what we do and the value we provide through our strong portfolio of cancer products, vaccines and therapies.”

Highlights of the newly designed RPC website include the following:

• Functional and Highly Intuitive Interface: RPC’s website was designed to provide ease of use, featuring a multi-level navigation that allows users to quickly access desired content.
• In-depth Investor Relations Section: includes investor highlights, RPC’s company history, and operations overview. In addition, this section offers RPC’s quote and data SEC filings, news releases, webcasts, analyst reports and information on the company’s strategic plans.
• Management: a listing of the company’s Directors and Executive Officers along with their respective bios and e-mail contacts.
• Product Portfolio and Associated Materials: A detailed overview of RPC’s product portfolio that includes clinical data and resources, regulatory and patent information, research and development initiatives, product innovations and relevant product news as it relates to our strategic plans and industry developments.
• Corporate Video: new video that provides in-depth details on RPC’s corporate and product commercialization strategy, timeline and progress.

Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is a US-based pharmaceutical company specializing in the research, development and sales of In Vitro Diagnostic Cancer tests. The Company’s focus is on the discovery, development & commercialization of unique high?value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve outcomes for patients. Our Onko?Sure™ IVD cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. For additional information on RPC and its portfolio of cancer products visit the Company’s corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.

About Radient Pharma:
Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is an integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, and premium skin care products.

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company